Theralase Technologies, Inc. (TLT) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

51.61 k

Shareholding (Dec 2022)

FII

0.05%

Held by 1 FIIs

DII

99.95%

Held by 0 DIIs

Promoter

0.00%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Mar 25

ROCE(HY) Lowest at -291.48%
DEBTORS TURNOVER RATIO(HY) Lowest at 1.55%
RAW MATERIAL COST(Y) Grown by 6,330% (YoY)

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 51 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.02

Return on Equity

-335.23%

Price to Book

39.80

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

14.9%

6 Months

19.32%

1 Year

-6.34%

2 Years

-36.06%

3 Years

-53.17%

4 Years

-48.98%

5 Years

-27.33%

Theralase Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

3.37%

EBIT Growth (5y)

7.98%

EBIT to Interest (avg)

-4.83

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.03

Sales to Capital Employed (avg)

0.57

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

38.83

EV to EBIT

-11.43

EV to EBITDA

-12.17

EV to Capital Employed

37.91

EV to Sales

46.43

PEG Ratio

Dividend Yield

ROCE (Latest)

-331.64%

ROE (Latest)

-335.23%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2022

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.05%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 100.00% vs -50.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 9.09% vs 8.33% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.90",
          "val2": "-1.10",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-1.10",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,438.10%",
          "val2": "-11,304.10%",
          "chgp": "686.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -9.09% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.52% vs 11.54% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.00",
          "val2": "1.10",
          "chgp": "-9.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.00",
          "val2": "-4.30",
          "chgp": "6.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.30",
          "val2": "-4.60",
          "chgp": "6.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,149.60%",
          "val2": "-4,292.50%",
          "chgp": "14.29%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.20

0.10

100.00%

Operating Profit (PBDIT) excl Other Income

-0.90

-1.10

18.18%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-1.00

-1.10

9.09%

Operating Profit Margin (Excl OI)

-4,438.10%

-11,304.10%

686.60%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 100.00% vs -50.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 9.09% vs 8.33% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

1.00

1.10

-9.09%

Operating Profit (PBDIT) excl Other Income

-4.00

-4.30

6.98%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.30

-4.60

6.52%

Operating Profit Margin (Excl OI)

-4,149.60%

-4,292.50%

14.29%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -9.09% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 6.52% vs 11.54% in Dec 2023

All Annual Results

Company CV

About Theralase Technologies, Inc.

Theralase Technologies, Inc.

Pharmaceuticals & Biotechnology

Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.

Company Coordinates

Company Details

41 Hollinger Rd , EAST YORK ON : M4B 3G4

Tel: 1 416 69952731 416 4478455

http://theralase.com/

Registrar Details